Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Poster: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)

Download PDF